

Project protocol for 'Vision screening in children under the age of 18 - a systematic review of effect studies'

Project number: RL 022

Protocol developed: April 2018

Short description/summary:

There is a lack of consensus concerning the effects, and cost-effectiveness, of vision screening in children, as well as the optimal age, the frequency and the intervals, at which to carry out screening. In Norway, all children are screened at birth, at 6 weeks of age, at 3 months, and at the age of 4 as part of the mandatory health checks. In contrast to guidance in the other Scandinavian countries, the Norwegian Guideline for Vision Screening in children recommend fewer pre-school screening events, and does not include any recommendations for screening of schoolchildren. Vision screening of children at different ages fulfill different purposes, e.g. pre-school screening to detect amblyopia (lazy eye), and related conditions, and screening of school-age children to detect refractive errors (blurred vision), and progressive visual deficits. Younger children are at risk of permanent impaired vision if deficits are not identified in time, while older children, do not risk permanent visual impairment if not screened. Un-detected visual deficits may impact negatively on the sensorimotor, intellectual and social development of children. This report will be a systematic review of the effects of vision screening in children on the detection of correctable visual deficits, referral to appropriate treatment and follow up of the children's vision.

Norsk oppsummering:

Det mangler konsensus om effekten og kostnadseffektiviteten av synsscreening av barn. Det er uenighet om den optimale alderen for screening samt hvor ofte og med hvilke tidsintervall det skal utføres screening. I dag screenes norske barn for synsfeil ved fødselen, ved 6-ukers, 3-måneders, og 4 års alder som en del av den obligatoriske helsekontrollen. I motsetning til retningslinjene i de andre skandinaviske landene, anbefaler den norske faglige retningslinjen for synsundersøkelse av barn færre screeninger av førskolebarn og det foreligger ikke anbefalinger om screening av barn i skolealder. Synsscreening av barn i ulike aldre har ulike formål, f.eks. er det primære formålet med screening av 4-åringer å oppdage amblyopi ('dovent øye') og relaterte tilstander, mens screening av skolebarn primært gjennomføres for å oppdage brytningsfeil og progressive tilstander i øyet. Yngre barn risikerer permanent nedsatt syn hvis synsfeil ikke fanges opp tidlig, mens eldre barn ikke risikerer permanent synsnedsettelse hvis de ikke screenes. Uidentifiserte synsproblemer kan innvirke negativt på barns sensorisk-motoriske, intellektuelle og sosiale utvikling. Denne rapporten skal bli en systematisk oversikt over effekter av synsscreening av barn på identifisering av korrigerbare synsproblemer, henvisning til adekvat behandling og oppfølging av barns syn.

Project category and commissioner

Product (program area): Systematic review

Thematic area: Vision/ eye health

Commissioner(s): the Directorate of Health,

Contact person: Astrid Hernes Kvalnes; E-mail: Astrid.Hernes.Kvalnes@helsedir.no

Project coordinator and working group

Project coordinator: Gerd M Flodgren

Project supervisor: Kjetil G Brurberg

Internal working group:

Gerd M Flodgren, Kristoffer Yunpeng Ding, Hilde Strømme

External collaborators: -

Contingency plan:

Mandate

The Norwegian Directorate of Health is updating the National guideline for vision screening in children [1]. The Division of Health Services at the Norwegian Institute of Public Health performs systematic reviews of priority questions for the work on national guidelines. This systematic review on vision screening in children under the age of 18 is conducted on this mandate from the Norwegian Directorate of Health.

Purpose

The overall objective of this systematic review is to summarise and critically appraise the existing evidence of the effects of vision screening in children (0 to 18 years) on the detection of correctable visual deficits, referral to adequate treatment and follow up of these children.

Definitions:

Vision screening is a short examination that can indicate the presence of a vision deficit or a potential vision problem. It does not provide an exact diagnosis, but can indicate a need of an appointment with an ophthalmologist or optometrist for a comprehensive eye examination.

Correctable visual deficits include e.g. amblyopia (if identified at an early age), strabismus, and refractive errors. Colour vision deficiency, on the other hand, is a condition that cannot be corrected, and screening for this condition is therefore outside the scope of this systematic review.

We have used the Oxford dictionary's definition of a child, which is "a young human being below the age of puberty or below the legal age of majority". In Norway, as in many other countries, this would refer to individuals under the age of 18.

Background

The aim of vision-screening programs for children is early detection of correctable visual deficits, timely referral to adequate treatment and follow up [2]. There is however, a lack of consensus regarding the effects, and cost-effectiveness, of universal screening programs [3, 4]. *Universal* screening programs, as opposed to targeted screening of high risk populations, include all children of a certain age.

Description of the problem

Visual deficits (in particular amblyopia), can have negative effects on the sensorimotor development of children, as well as on their intellectual and social development [5-7]. Common visual deficits in pre-school children that can be detected through screening, are amblyopia, strabismus and refractive errors [5]. Amblyopia (or lazy eye), which is the most common cause of visual impairment in children, is a functional reduction in visual acuity resulting from an abnormal visual development early in life [8]. Amblyopia may be related to eye diseases, refractive errors and strabismus [5]. Treatment of amblyopia is most effective when initiated early [9].

There is a lack of consensus concerning the effects of vision screening in children, as well as the optimal age [10, 11], the frequency, and intervals, at which to carry out screening. In Norway, all children, are screened at birth, at 6 weeks, 3 months, and again at age 4 as part of the mandatory health check [1]. In contrast to the vision screening guidance in Sweden, Denmark, and Finland, the Norwegian Guideline for Vision Screening in children, involve comparatively fewer screening events in total, and include no recommendation for screening of school-aged children [12]. School-aged children in Norway are referral to an eye examination based on indications of poor vision, expressed by the child, its parents or teachers [1].

Vision screening of children at different ages fulfil different purposes; e.g. screening of infants to detect congenital cataract[13]; screening of pre-school children to detect amblyopia, and conditions that may lead to amblyopia, while screening of school-children is primarily used to detect refractive errors, and progression of visual deficits [14]. It should however be noted that lack of screening have completely different consequences for different age groups. While younger children are at risk of permanent impaired vision (even with ideal glasses), if important visual deficits are not detected and treated in time, children who are older, do not run the same risk of permanent visual impairment if not screened. There is some new evidence, from a large longitudinal Indian study, suggesting that school-children's eye-sight are getting increasingly worse [15]. However, it is unclear whether these findings can be generalised to a Norwegian context, and if universal screening is the best way to solve this problem.

How the intervention might work?

Vision screening programs may improve the eye health of a population through early detection of correctable visual deficits in childhood, timely referral for adequate treatment and follow up of relevant children [2].

Most high-income countries have vision-screening programs in place, but these may differ in both content and scope. Worldwide, there is large variation in screening practices, both across and within countries [2, 16]. For example, in Canada [10], and Australia [2], the screening practices varies widely within each country, which may give rise to inequities in eye health among children from different regions.

According to an inventory of current paediatric vision screening in Europe, a majority of participating countries (35 out of 39 countries) have national screening programmes in place, with half of the countries reporting 95% coverage or more [6, 10]. In the participating European countries vision screening is performed at a varying frequency, at different points in time (e.g. preschool screening between 3 and 7 years of age), by varying professions (most often ophthalmologists, paediatricians and nurses), and using a number of different vision acuity tests (e.g. Picture chart, Lea Hyvarinen chart (LH), Landolt, Tumbling E, Konstantin Moutakis, Sheridan Gardiner and Snellen)[6].

Why is it important to do this review?

The Directorate of Health are updating the National Guideline for Vision screening in Children [1], and wishes to gain knowledge about new, and the complete evidence regarding the effects (and cost-effectiveness) of vision screening programs. This systematic review will assist this process by updating the evidence-base upon which this guidance will be informed.

Early detection, and treatment, of visual deficits (especially amblyopia, and related conditions) have the potential to improve eye development and visual function, by decreasing both the prevalence and severity of amblyopia [8]. If detection of visual deficits is improved by more screenings, more children will receive treatment and gain improved vision development. It is therefore important to systematically review the existing evidence on the effects of vision screening in children, to ensure that the new guideline includes the most recent research evidence.

In a recent Cochrane systematic review, the authors searched for randomised controlled studies evaluating the effects of vision screening versus no screening for school-aged children and adolescents, but found no eligible studies [3]. In another Cochrane review, the authors searched for randomised studies comparing amblyopia prevalence among previously screened and unscreened children at school start, but identified no eligible studies [4]. It is therefore desirable to search for both randomised, and non-randomised controlled studies comparing the effects of vision screening with no screening (or different intensity of screening) in children under the age of 18 (i.e. both pre-school and school aged children).

Methods

We will conduct this systematic review in accordance with the methods described in the Cochrane Handbook for Systematic Reviews of Interventions [17] and in the Division of Health Services' handbook [18] as specified below:

Search methods for identification of studies

Research librarian Hilde Strømme (HS) will develop the search strategy based on our inclusion criteria (see below), and another research librarian will peer review the search strategy, which will have no language restrictions. HS will conduct the searches in the following databases:

- Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials Register)
- MEDLINE (Ovid)
- Embase (Ovid)
- SveMed+
- DARE, EED, and HTA database (via the Cochrane Library)
- Epistemonikos

We will search all databases for publications from their respective inception date.

Searching other sources

We will search for grey literature in OpenGrey and GreyLit. In addition, we will search the reference lists of studies eligible for inclusion.

Selection of studies

We will download all titles and abstracts retrieved by the electronic searches into the reference management program EndNote and remove duplicates. Two review authors (GMF and KYD) will independently assess the eligibility of all the remaining titles and abstracts for inclusion. We will obtain full text copies of potentially relevant studies, and assess these against the inclusion criteria (see below). We will resolve disagreements on the eligibility of studies by discussion among review authors. We will document studies read in full text, and subsequently excluded, in a table along with the reasons for exclusion.

Inclusion criteria:

- Population:** Children under the age of 18
- Intervention:** Vision screening (conducted in any setting, and by any trained personnel, using any standardised tests).
- Comparison:**
- No screening
 - Different screening intensity (frequency of screening and screening intervals)

- Outcomes:** Primary outcomes: Detection of correctable visual acuity deficits; referral to appropriate treatment and follow up plans, vision outcomes (e.g. visual acuity, strabismus, refractive error)
Secondary outcomes: quality of life, academic performance
- Study design**
- Systematic reviews (SRs)
 - Randomised controlled trials (RCTs)
 - Cluster RCTs
 - Non-randomised controlled trials (NRCT)
 - Controlled before-after studies (CBAs)
 - Interrupted time series studies (ITSS)
 - Prospective controlled cohort studies
- Language:** We consider all relevant studies for inclusion regardless of language.

If we find one, or more, SRs that answers the research questions, and that includes studies eligible for inclusion in this systematic review, we will report the results of these reviews, and not included original papers. If we do not find any eligible SRs, but a sufficient number of RCTs, we will not include non-randomised or observational studies.

Exclusion criteria:

We will exclude studies that evaluate the effects of targeted screening i.e. screening targeted at specific populations of children considered to be at greater risk for developing visual deficits (e.g. prematurity, low birth weight, first degree relative with amblyopia). We will exclude conference abstracts, and other publications without results in full text.

Assessment of methodological quality:

Two review authors (GMF and KYD), will independently assess the risk of bias of each included study in accordance to the guidance in Chapter 8 of the Cochrane Handbook for Systematic Reviews of Interventions [19]. We will use the Cochrane Effective Practice and Organisation of Care (EPOC) group's risk of bias tool [20] when assessing RCTs, NRCTs, and CBA studies. We will assess the following items: i) sequence generation; ii) concealment of allocation; iii) blinded or objective assessment of primary outcome(s); iv) incomplete outcome data; v) selective reporting; vi) other risk of bias; vii) baseline characteristics, and viii) baseline outcome measures. We will use the ROBIS-I tool to assess the risk of bias of observational studies (e.g. controlled cohort studies) [21]. We will assign an overall assessment of the risk of bias (high, unclear or low risk of bias) to each of the included studies using the approach suggested in Chapter 8 of the Cochrane Handbook [19]. We will resolve any disagreements through consensus.

Data extraction and analysis:

One review author (GMF) will extract data from each included study into a standardised data extraction form (<http://epoc.cochrane.org/resources/epoc-resources-review-authors>), and a

second review author (KYD) will control the accuracy of the data. We will resolve disagreements through consensus.

We will extract the following data from the included primary studies:

- Full reference; study design,
- Characteristics of the population e.g. no of participants, age, gender, ethnicity; adherence to screening and follow up
- Type of vision deficits e.g. amblyopia, strabismus, refractive errors;
- Country;
- Screening context i.e. healthcare setting or school healthcare;
- Characteristics of the intervention e.g. number and intervals between screening events, vision tests used, including failure thresholds applied for specific tests, and whether or not the tests used are considered age appropriate; and their diagnostic accuracy;
- Profession and qualifications of those conducting the screening;
- Type of comparison intervention (i.e. no screening, different screening intensity),
- Outcomes (Primary: successful detection of vision deficits, referral to appropriate treatment and follow up; Secondary: quality of life, academic performance).

For dichotomous outcomes, we will express the results as a risk ratio (RR) with 95% confidence interval (CI). For continuous outcomes, we will use mean difference between the groups (MD) with 95% CI, if necessary converted to standardised mean difference (SMD). If this is not possible, we will provide a narrative description of the results. We will summarise and report results from studies with different study designs separately (e.g. RCT, NRCTs, CBA and ITSs). We will evaluate the heterogeneity of the material by looking at population, intervention, comparison and outcomes. If it is feasible to conduct meta-analysis, we will evaluate statistical heterogeneity using Q test and I^2 , where we will consider a significance level of $p < 0.05$ to indicate heterogeneity. I^2 values of 25% or less will indicate low heterogeneity, values of 50-75% will indicate moderate heterogeneity, and more than 75% high heterogeneity. We will conduct any meta-analyses in the RevMan 5 program [22], according to guidance provided in the Cochrane handbook [17]. If it is not possible to pool the data, we will provide a descriptive analysis with presentation of the studies in the text, and in tables with results and quality assessments.

Grading of the certainty of the evidence

Two review authors (GMF and KYD) will together assess our certainty of the evidence (i.e. to what degree we trust that the results estimate the true effect) using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) handbook [23], and tool [24].

Evidence from randomised controlled trials start as high certainty evidence, evidence from observational studies start at low certainty. Both may be downgraded depending on five criteria in GRADE that are used to determine the certainty of the evidence: i) methodological study quality as assessed by review authors, ii) degree of inconsistency, iii) indirectness, iv) imprecision, and v) publication bias. Upgrading of results from observational studies (with no study limitations) is possible according to GRADE if there is a large effect estimate, or a dose-

response gradient, or if all possible confounders would only diminish the observed effect and that therefore the actual effect most likely is larger than what the data suggest.

In accordance with the GRADE approach, we will grade the certainty of the evidence as high, moderate, low, or very low, which is defined in the following way:

High certainty: We are very confident that the true effect lies close to that of the estimate of the effect

Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

Ethics

We will not address ethical considerations of vision screening in this systematic review.

Activities and timetable

Gantt-diagram:

Oppgave	Ansvarlig	Startdato	Kalender- tid i dager	Sluttdato	Reelt tidsforbruk i mnd-verk (overføres budsjettet)
Skrive prosjektplan	GMF	15.03.18	14	16.04.18	Incl.30 days annual leave
Fagfellelvurdering av prosjektplan	GMF	17.04.18	21	09.05.18	
Få godkjent prosjektplan	GMF	10.05.18	7	16.05.18	
Søke etter litteratur	HS	17.05.18	10	27.05.18	
Velge ut studier	GMF, KYD	28.05.18	5	01.06.15	
Vurdere studienes metodiske kvalitet	GMF, KYD	02.06.18	5	08.06.18	
Hente ut data, sammenstille og gradere	GMF, KYD	11.06.18	21	29.06.18	
Skrive utkast rapport	GMF	02.07.18	21	20.08.18	
Fagfellelvurdering av rapport	GMF	21.08.18	21	05.09.18	
Skrive ferdig rapport	GMF	06.09.18	14	17.09.18	
Godkjenne og publisere	GMF	18.09.18	14	30.09.18	

1 13 26 39 52 65 78 91 104 117 130 143 156 169 182 195 208 221 234 247 260 273 286 299 312 325 338 351 364 377 390 403 416 429 442 455 468 481 494 507 520 533 546 559 572 585 598 611 624 637 650 663 676 689 702 715 728 741 754 767 780 793 806 819 832 845 858 871 884 897 910 923 936 949 962 975 988 1001 1014 1027 1040 1053 1066 1079 1092 1105 1118 1131 1144 1157 1170 1183 1196 1209 1222 1235 1248 1261 1274 1287 1300 1313 1326 1339 1352 1365 1378 1391 1404 1417 1430 1443 1456 1469 1482 1495 1508 1521 1534 1547 1560 1573 1586 1599 1612 1625 1638 1651 1664 1677 1690 1703 1716 1729 1742 1755 1768 1781 1794 1807 1820 1833 1846 1859 1872 1885 1898 1911 1924 1937 1950 1963 1976 1989 2002 2015 2028 2041 2054 2067 2080 2093 2106 2119 2132 2145 2158 2171 2184 2197 2210 2223 2236 2249 2262 2275 2288 2301 2314 2327 2340 2353 2366 2379 2392 2405 2418 2431 2444 2457 2470 2483 2496 2509 2522 2535 2548 2561 2574 2587 2600 2613 2626 2639 2652 2665 2678 2691 2704 2717 2730 2743 2756 2769 2782 2795 2808 2821 2834 2847 2860 2873 2886 2899 2912 2925 2938 2951 2964 2977 2990 3003 3016 3029 3042 3055 3068 3081 3094 3107 3120 3133 3146 3159 3172 3185 3198 3211 3224 3237 3250 3263 3276 3289 3302 3315 3328 3341 3354 3367 3380 3393 3406 3419 3432 3445 3458 3471 3484 3497 3510 3523 3536 3549 3562 3575 3588 3601 3614 3627 3640 3653 3666 3679 3692 3705 3718 3731 3744 3757 3770 3783 3796 3809 3822 3835 3848 3861 3874 3887 3900 3913 3926 3939 3952 3965 3978 3991 4004 4017 4030 4043 4056 4069 4082 4095 4108 4121 4134 4147 4160 4173 4186 4199 4212 4225 4238 4251 4264 4277 4290 4303 4316 4329 4342 4355 4368 4381 4394 4407 4420 4433 4446 4459 4472 4485 4498 4511 4524 4537 4550 4563 4576 4589 4602 4615 4628 4641 4654 4667 4680 4693 4706 4719 4732 4745 4758 4771 4784 4797 4810 4823 4836 4849 4862 4875 4888 4901 4914 4927 4940 4953 4966 4979 4992 5005 5018 5031 5044 5057 5070 5083 5096 5109 5122 5135 5148 5161 5174 5187 5200 5213 5226 5239 5252 5265 5278 5291 5304 5317 5330 5343 5356 5369 5382 5395 5408 5421 5434 5447 5460 5473 5486 5499 5512 5525 5538 5551 5564 5577 5590 5603 5616 5629 5642 5655 5668 5681 5694 5707 5720 5733 5746 5759 5772 5785 5798 5811 5824 5837 5850 5863 5876 5889 5902 5915 5928 5941 5954 5967 5980 5993 6006 6019 6032 6045 6058 6071 6084 6097 6110 6123 6136 6149 6162 6175 6188 6201 6214 6227 6240 6253 6266 6279 6292 6305 6318 6331 6344 6357 6370 6383 6396 6409 6422 6435 6448 6461 6474 6487 6500 6513 6526 6539 6552 6565 6578 6591 6604 6617 6630 6643 6656 6669 6682 6695 6708 6721 6734 6747 6760 6773 6786 6799 6812 6825 6838 6851 6864 6877 6890 6903 6916 6929 6942 6955 6968 6981 6994 7007 7020 7033 7046 7059 7072 7085 7098 7111 7124 7137 7150 7163 7176 7189 7202 7215 7228 7241 7254 7267 7280 7293 7306 7319 7332 7345 7358 7371 7384 7397 7410 7423 7436 7449 7462 7475 7488 7501 7514 7527 7540 7553 7566 7579 7592 7605 7618 7631 7644 7657 7670 7683 7696 7709 7722 7735 7748 7761 7774 7787 7800 7813 7826 7839 7852 7865 7878 7891 7904 7917 7930 7943 7956 7969 7982 7995 8008 8021 8034 8047 8060 8073 8086 8099 8112 8125 8138 8151 8164 8177 8190 8203 8216 8229 8242 8255 8268 8281 8294 8307 8320 8333 8346 8359 8372 8385 8398 8411 8424 8437 8450 8463 8476 8489 8502 8515 8528 8541 8554 8567 8580 8593 8606 8619 8632 8645 8658 8671 8684 8697 8710 8723 8736 8749 8762 8775 8788 8801 8814 8827 8840 8853 8866 8879 8892 8905 8918 8931 8944 8957 8970 8983 8996 9009 9022 9035 9048 9061 9074 9087 9100 9113 9126 9139 9152 9165 9178 9191 9204 9217 9230 9243 9256 9269 9282 9295 9308 9321 9334 9347 9360 9373 9386 9399 9412 9425 9438 9451 9464 9477 9490 9503 9516 9529 9542 9555 9568 9581 9594 9607 9620 9633 9646 9659 9672 9685 9698 9711 9724 9737 9750 9763 9776 9789 9802 9815 9828 9841 9854 9867 9880 9893 9906 9919 9932 9945 9958 9971 9984 9997 10010 10023 10036 10049 10062 10075 10088 10101 10114 10127 10140 10153 10166 10179 10192 10205 10218 10231 10244 10257 10270 10283 10296 10309 10322 10335 10348 10361 10374 10387 10400 10413 10426 10439 10452 10465 10478 10491 10504 10517 10530 10543 10556 10569 10582 10595 10608 10621 10634 10647 10660 10673 10686 10699 10712 10725 10738 10751 10764 10777 10790 10803 10816 10829 10842 10855 10868 10881 10894 10907 10920 10933 10946 10959 10972 10985 10998 11011 11024 11037 11050 11063 11076 11089 11102 11115 11128 11141 11154 11167 11180 11193 11206 11219 11232 11245 11258 11271 11284 11297 11310 11323 11336 11349 11362 11375 11388 11401 11414 11427 11440 11453 11466 11479 11492 11505 11518 11531 11544 11557 11570 11583 11596 11609 11622 11635 11648 11661 11674 11687 11700 11713 11726 11739 11752 11765 11778 11791 11804 11817 11830 11843 11856 11869 11882 11895 11908 11921 11934 11947 11960 11973 11986 11999 12012 12025 12038 12051 12064 12077 12090 12103 12116 12129 12142 12155 12168 12181 12194 12207 12220 12233 12246 12259 12272 12285 12298 12311 12324 12337 12350 12363 12376 12389 12402 12415 12428 12441 12454 12467 12480 12493 12506 12519 12532 12545 12558 12571 12584 12597 12610 12623 12636 12649 12662 12675 12688 12701 12714 12727 12740 12753 12766 12779 12792 12805 12818 12831 12844 12857 12870 12883 12896 12909 12922 12935 12948 12961 12974 12987 13000 13013 13026 13039 13052 13065 13078 13091 13104 13117 13130 13143 13156 13169 13182 13195 13208 13221 13234 13247 13260 13273 13286 13299 13312 13325 13338 13351 13364 13377 13390 13403 13416 13429 13442 13455 13468 13481 13494 13507 13520 13533 13546 13559 13572 13585 13598 13611 13624 13637 13650 13663 13676 13689 13702 13715 13728 13741 13754 13767 13780 13793 13806 13819 13832 13845 13858 13871 13884 13897 13910 13923 13936 13949 13962 13975 13988 14001 14014 14027 14040 14053 14066 14079 14092 14105 14118 14131 14144 14157 14170 14183 14196 14209 14222 14235 14248 14261 14274 14287 14300 14313 14326 14339 14352 14365 14378 14391 14404 14417 14430 14443 14456 14469 14482 14495 14508 14521 14534 14547 14560 14573 14586 14599 14612 14625 14638 14651 14664 14677 14690 14703 14716 14729 14742 14755 14768 14781 14794 14807 14820 14833 14846 14859 14872 14885 14898 14911 14924 14937 14950 14963 14976 14989 15002 15015 15028 15041 15054 15067 15080 15093 15106 15119 15132 15145 15158 15171 15184 15197 15210 15223 15236 15249 15262 15275 15288 15301 15314 15327 15340 15353 15366 15379 15392 15405 15418 15431 15444 15457 15470 15483 15496 15509 15522 15535 15548 15561 15574 15587 15600 15613 15626 15639 15652 15665 15678 15691 15704 15717 15730 15743 15756 15769 15782 15795 15808 15821 15834 15847 15860 15873 15886 15899 15912 15925 15938 15951 15964 15977 15990 16003 16016 16029 16042 16055 16068 16081 16094 16107 16120 16133 16146 16159 16172 16185 16198 16211 16224 16237 16250 16263 16276 16289 16302 16315 16328 16341 16354 16367 16380 16393 16406 16419 16432 16445 16458 16471 16484 16497 16510 16523 16536 16549 16562 16575 16588 16601 16614 16627 16640 16653 16666 16679 16692 16705 16718 16731 16744 16757 16770 16783 16796 16809 16822 16835 16848 16861 16874 16887 16900 16913 16926 16939 16952 16965 16978 16991 17004 17017 17030 17043 17056 17069 17082 17095 17108 17121 17134 17147 17160 17173 17186 17199 17212 17225 17238 17251 17264 17277 17290 17303 17316 17329 17342 17355 17368 17381 17394 17407 17420 17433 17446 17459 17472 17485 17498 17511 17524 17537 17550 17563 17576 17589 17602 17615 17628 17641 17654 17667 17680 17693 17706 17719 17732 17745 17758 17771 17784 17797 17810 17823 17836 17849 17862 17875 17888 17901 17914 17927 17940 17953 17966 17979 17992 18005 18018 18031 18044 18057 18070 18083 18096 18109 18122 18135 18148 18161 18174 18187 18200 18213 18226 18239 18252 18265 18278 18291 18304 18317 18330 18343 18356 18369 18382 18395 18408 18421 18434 18447 18460 18473 18486 18499 18512 18525 18538 18551 18564 18577 18590 18603 18616 18629 18642 18655 18668 18681 18694 18707 18720 18733 18746 18759 18772 18785 18798 18811 18824 18837 18850 18863 18876 18889 18902 18915 18928 18941 18954 18967 18980 18993 19006 19019 19032 19045 19058 19071 19084 19097 19110 19123 19136 19149 19162 19175 19188 19201 19214 19227 19240 19253 19266 19279 19292 19305 19318 19331 19344 19357 19370 19383 19396 19409 19422 19435 19448 19461 19474 19487 19500 19513 19526 19539 19552 19565 19578 19591 19604 19617 19630 19643 19656 19669 19682 19695 19708 19721 19734 19747 19760 19773 19786 19799 19812 19825 19838 19851 19864 19877 19890 19903 19916 19929 19942 19955 19968 19981 19994 20007 20020 20033 20046 20059 20072 20085 20098 20111 20124 20137 20150 20163 20176 20189 20202 20215 20228 20241 20254 20267 20280 20293 20306 20319 20332 20345 20358 20371 20384 20397 20410 20423 20436 20449 20462 20475 20488 20501 20514 20527 20540 20553 20566 20579 20592 20605 20618 20631 20644 20657 20670 20683 20696 20709 20722 20735 20748 20761 20774 20787 20800 20813 20826 20839 20852 20865 20878 20891 20904 20917 20930 20943 20956 20969 20982 20995 21008 21021 21034 21047 21060 21073 21086 21099 21112 21125 21138 21151 21164 21177 21190 21203 21216 21229 21242 21255 21268 21281 21294 21307 21320 21333 21346 21359 21372 21385 21398 21411 21424 21437 21450 21463 21476 21489 21502 21515 21528 21541 21554 21567 21580 21593 21606 21619 21632 21645 21658 21671 21684 21697 21710 21723 21736 21749 21762 21775 21788 21801 21814 21827 21840 21853 21866 21879 21892 21905 21918 21931 21944 21957 21970 21983 21996 22009 22022 22035 22048 22061 22074 22087 22100 22113 22126 22139 22152 22165 22178 22191 22204 22217 22230 22243 22256 22269 22282 22295 22308 22321 22334 22347 22360 22373 22386 22399 22412 22425 22438 22451 22464 22477 22490 22503 22516 22529 22542 22555 22568 22581 22594 22607 22620 22633 22646 22659 22672 22685 22698 22711 22724 22737 22750 22763 22776 22789 22802 22815 22828 22841 22854 22867 22880 22893 22906 22919 22932 22945 22958 22971 22984 22997 23010 23023 23036 23049 23062 23075 23088 23101 23114 23127 23140 23153 23166 23179 23192 23205 23218 23231 23244 23257 23270 23283 23296 23309 23322 23335 23348 23361 23374 23387 23400 23413 23426 23439 23452 23465 23478 23491 23504 23517 23530 23543 23556 23569 23582 23595 23608 23621 23634 23647 23660 23673 23686 23699 23712 23725 23738 23751 23764 23777 23790 23803 23816 23829 23842 23855 23868 23881 23894 23907 23920 23933 23946 23959 23972 23985 23998 24011 24024 24037 24050 24063 24076 24089 24102 24115 24128 24141 24154 24167 24180 24193 24206 24219 24232 24245 24258 24271 24284 24297 24310 24323 24336 24349 24362 24375 24388 24401 24414 24427 24440 24453 24466 24479 24492 24505 24518 24531 24544 24557 24570 24583 24596 24609 24622 24635 24648 24661 24674 24687 24700 24713 24726 24739 24752 24765 24778 24791 24804 24817 24830 24843 24856 24869 24882 24895 24908 24921 24934 24947 24960 24973 24986 24999 25012 25025 25038 25051 25064 25077 25090 25103 25116 25129 25142 25155 25168 25181 25194 25207 25220 25233 25246 25259 25272 25285 25298 25311 25324 25337 25350 25363 25376 25389 25402 25415 25

Peer review

This systematic review protocol, and the full review, will be peer reviewed by two internal people with methodological expertise and two external peer reviewers with relevant clinical expertise.

Publication/research dissemination

We will publish the systematic review as a FHI report on our website. The language is English. The target audiences are the commissioners (the Directorate of Health), decision makers, interest groups and educational institutions, and the public. We will send the report electronically to the commissioner before publication. Publishing in the form of an international publication, and/or a popular science article, or similar, to relevant professions will be considered.

Risk analysis

RISK	PROBABILITY	CONSEQUENCE	RISK FACTOR
Long term sick-leave	Low risk	Delayed report	Low
Measures to limit the probability of risk and consequences:	Assign new project manager/staff		

References

1. Sosial- og Helsedirektoratet, *Retningslinjer for undersøkelse av syn, hørsel og språk hos barn*, Helsedirektoratet, Editor. 2005: Oslo.
2. Hopkins, S., Sampson, G.P, Hendicott, P, Wood, J.M, *Review of guidelines for children's vision screenings*. Clin Exp Optom 2013. **96**: p. 443-9.
3. Evans, J., Morjaria, P, Powell, C, *Vision screening for correctable visual acuity deficits in school-age children and adolescents* Cochrane Database of Systematic Reviews 2018(2).
4. Powell, C., Hatt, S.R, *Vision screening for amblyopia in childhood*. Cochrane Database of Systematic Reviews 2009(3).
5. Institute of Health Economics, *The safety and effectiveness of preschool vision screening*. 2012, Institute of Health Economics: Edmonton.
6. Sloot, F., Hoeve, H.L, de Kroon, M. L, Goedegebure, A, Carlton, J, Griffiths, H.J, Simonsz, H.J, *Inventory of current EU paediatric vision and hearing screening programmes*. Journal of Medical Screening, 2015. **22**(2): p. 55-64.
7. White, S.L.J., wood, J.M, Black, A.A, Hopkins, S, *Vision screening outcomes of Grade 3 children in Australia: Differences in academic achievement*. International Journal of Educational Research, 2017. **83**: p. 154-9.
8. Coats, D.K., Paysse, E.A *Amblyopia in children: Classification, screening, and evaluation*. UpToDate 2018 [cited 2018 16.04.18 at <https://www.uptodate.com/contents/amblyopia-in-children-classification-screening-and-evaluation>].
9. Coats, D., Paysse, EA *Amblyopia in children: classification, screening and evaluation*, R. Saunders, Armsby, CA, Editor. 2018.

10. Mema, S.C., McIntyre, L, Musto, R, *Childhood Vision Screening in Canada: Public Health Evidence and Practice*. Can J Public Health, 2011. **103**(1): p. 40-5.
11. Nørregaard, J.C., Kruse, M, Olsen, J, *Synscreening af førskolebarn- en kommenteret udenlandsk medicinsk teknologivurdering*, in *Kommenteret Udenlandsk Medicinsk Teknologivurdering*. 2010, Sundhedsstyrelsen, Monitorering & Medicinsk teknologivurdering: København.
12. Socialstyrelsen, *Sammanställning av vägledande dokument för barn- och skolhälsovård– Danmark, England, Finland, Norge och Sverige*. 2012, Socialstyrelsen: Sverige.
13. Cagini, C., Tosi, G, Stracci, F, Rinaldi, VE, Verrotti, A, *The red reflex examination in neonates*. International Journal of Ophthalmology, 2016. **37**(5): p. 1199–1204.
14. Logan, N.S., Gilmartin, B, *School vision screening, ages 5–16 years: the evidence-base for content, provision and efficacy*. Ophthalmic and Physiological Optics, 2004. **24**(6): p. 481-92.
15. Saxena, R., et al., *Incidence and progression of myopia and associated factors in urban school children in Delhi: The North India Myopia Study (NIM Study)*. PLoS ONE [Electronic Resource], 2017. **12**(12): p. e0189774.
16. Sharma, A., Congdon, N, Patel, M, Gilbert, C, *School-based approaches to the correction of refractive error in children*. Survey of Ophthalmology, 2012. **57**(3): p. 272-83.
17. Cochrane Collaboration, *Cochrane Handbook for Systematic Reviews of Interventions* J.P.T. Higgins, Green, S Editor. 2011.
18. Kunnskapscenteret, *Slik oppsummerer vi forskning*, in *Håndbok for Nasjonalt kunnskapscenter for helsetjenesten* 2015.
19. Cochrane Collaboration, *Chapter 8: Assessing risk of bias in included studies*, in *Cochrane Handbook for Systematic Reviews of Interventions*, J.P.T. Higgins, Green, S Editor. 2011, Cochrane Collaboration.
20. Cochrane Effective Practice and Organisation of Care group (EPOC). *Suggested risk of bias criteria for EPOC reviews. EPOC resources for review authors*. 2017 [cited 2018 Accessed 18 April 2018 at epoc.cochrane.org/epoc-resources-review-authors].
21. Sterne, J., Hernán, MA, Reeves, BC, Savović, J, Berkman, ND, Viswanathan, M, et al *ROBINS-I: a tool for assessing risk of bias in non-randomized studies of interventions*. British Medical Journal, 2016. **355**: p. i4919.
22. The Nordic Cochrane Centre, T.C.C., *Review Manager (RevMan)* 2014: Copenhagen.
23. The GRADE Working Group, *GRADE handbook for grading quality of evidence and strength of recommendations*, H. Schünemann, Brožek, J, Guyatt, G, Oxman, A, Editor. 2013.
24. The GRADE Working Group, *GRADEpro GDT: GRADEpro Guideline Development Tool [Software]*. 2015, McMaster University(developed by Evidence Prime, Inc.): Canada.